

| | | |
|--|-----------------------------|------------|
| PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. C1041/7005 | SERIAL NO. |
| | APPLICANT: Lipford, et al. | |
| | FILING DATE July 23, 1999 | GROUP |

U.S. PATENT DOCUMENTS

| Exam Init | Ref Des | Document No. | Date | Name | Class | Sub Class | FILING DATE If Appropriate |
|--------------|------------|--------------|----------|-------------------|-------|--------------|-------------------------------|
| 83 | A1 | 3,906,092 | 09/16/99 | Hilleman et al. | 424 | 89 | |
| | A2 | 5,248,670 | 09/28/93 | Draper et al. | 514 | 44 | |
| | A3 | 5,585,479 | 12/17/96 | Hoke et al. | 536 | 24.5 | |
| | A4 | 5,328,987 | 07/12/94 | Maliszewski | 530 | 350 | |
| | A5 | 5,663,153 | 09/02/97 | Hutcherson et al. | 514 | 44 | |
| | A6 | 5,849,719 | 12/15/98 | Carson et al. | 514 | 44 | 10/04/96 |


FOREIGN PATENT DOCUMENTS

| | | Country & Doc. No. (11) | Pub. Date (43) | | Class | Sub Class | Translation Yes No |
|----|-----|----------------------------|-------------------|-----------------------------|-------|--------------|-----------------------|
| 83 | B1 | EP 0 468 520 A3 | 01/29/92 | EPO | A61K | 31/70 | |
| | B2 | EP 0 302 758 A1 | 03/16/94 | EPO | C12N | 15/37 | |
| | B3 | WO 91/12811 | 09/05/91 | PCT | A61K | 31/70 | |
| | B4 | WO 92/03456 | 03/05/92 | PCT | C07H | 15/12 | |
| | B5 | WO 92/18522 | 10/29/92 | PCT | C07H | 21/00 | |
| | B6 | WO 92/21353 | 12/10/92 | PCT | A61K | 31/70 | |
| | B7 | WO 94/19945 | 09/15/94 | PCT | A01N | 43/04 | |
| | B8 | WO 95/05853 | 03/02/95 | PCT | A61K | 48/00 | |
| | B9 | WO 95/26204 | 10/05/95 | PCT | A61K | 48/00 | |
| | B10 | WO 96/02555 | 02/01/96 | PCT | C07H | 21/00 | |
| | B11 | WO 96/35782 | 11/14/96 | PCT | C12N | 15/11 | |
| | B12 | WO 98/14210 | 04/09/98 | PCT | A61K | 39/35 | |
| | B13 | WO 98/18810 | 05/07/98 | PCT | C07H | 21/00 | |
| | B14 | WO 98/37919 | 09/03/98 | PCT | A61K | 49/00 | |
| | B15 | WO 98/40100 | 09/17/98 | PCT | A61K | 39/39 | |
| | B16 | WO 98/52581 | 11/26/98 | PCT | A61K | 35/00 | |
| | B17 | PCT/EP98/00367 | 08/07/98 | International Search Report | | | |

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)


| | | |
|----|----|--|
| 83 | C1 | Adya N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> 91(12):5642-6, 7 Jun 1994. |
| | C2 | Arany Z et al., E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. <i>Cell</i> 77(6):799-800, 17 Jun 1994. |
| | C3 | Arias J et al., Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. <i>Nature</i> 370:226-9, 21 Jul 1994. |
| | C4 | Asiedu CK et al., Binding of AP-1/CREB proteins and of MDPB to contiguous sites downstream of the human TGF-beta 1 gene. <i>Biochim Biophys Acta</i> 1219(1):55-63, 13 Sep 1994. |
| | C5 | Azad RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. <i>Antimicrob Agents Chemother</i> 37(9):1945-54, Sep 1993. |



| PTO-1000 (Modified) | | | ATTY. DOCKET NO. C1041/7005 | SERIAL NO. |
|---|-----|---|-----------------------------|------------|
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT | | | APPLICANT: Lipford, et al. | |
| | | | FILING DATE July 22, 1999 | GROUP |
| 82 | C6 | Azuma I et al., Biochemical and immunological studies on cellular components of tubercle bacilli. <i>Kekkaku</i> 67(9):625-631, 1992. | | |
| | C7 | Blaxter ML et al., Genes expressed in <i>Brugia malayi</i> infective third stage larvae. <i>Mol Biochem Parasitol</i> 77(1):77-93, Apr 1996. | | |
| | C8 | Briskin M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation. <i>Mol Cell Biol</i> 10(1):422-5, Jan 1990. | | |
| | C9 | Crosby SD et al., The early response gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGCG (GSG) element-binding protein family. <i>Mol Cell Biol</i> 11(8):3835-41, Aug 1991. | | |
| | C10 | Crystal RG, Transfer of genes to humans: early lessons and obstacles to success. <i>Science</i> 270(5235):404-10, 20 Oct 1995. | | |
| | C11 | Du W and Maniatis T, An ATF/CREB binding site is required for virus induction of the human interferon beta gene. <i>Proc Natl Acad Sci USA</i> 89(6):2150-4, Mar 1992. | | |
| | C12 | Du W et al., Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements. <i>Cell</i> 74(5):887-98, 10 Sep 1993. | | |
| | C13 | Englisch et al., Chemically modified oligonucleotides as probes and inhibitors. <i>Angew Chem Int Ed Engl</i> 30:613-629, 1991. | | |
| | C14 | Ferreri K et al., The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex. <i>Proc Natl Acad Sci USA</i> 91(4):1210-3, Feb 1994. | | |
| | C15 | Gray GD et al., Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. <i>Cancer Res</i> 53(3):577-80, 1 Feb 1993. | | |
| | C16 | Highfield PE, Sepsis: the more, the murkier. <i>Biotechnology</i> 12(8):828, Aug 1994. | | |
| | C17 | Himes SR et al., HTLV-1 tax activation of the GM-CSF and G-CSF promoters requires the interaction of NF-kB with other transcription factor families. <i>Oncogene</i> 8(12):3189-97, Dec 1993. | | |
| | C18 | Huang D et al., Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes. <i>Mol Cell Biol</i> 14(6):4233-43, Jun 1994. | | |
| | C19 | Iguchi-Ariga SM and Schaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> 3(5):612-9, May 1989. | | |
| | C20 | Kataoka T et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> 83(3):244-7, Mar 1992. | | |
| | C21 | Kimura Y et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. <i>J Biochem (Tokyo)</i> 116(5):991-4, Nov 1994. | | |
| | C22 | Kline JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> 44(7):380A, 1996. | | |
| | C23 | Kline JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. <i>J Invest Med</i> 45(3):282A, 1997. | | |
| | C24 | Kline JN et al., CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> 45(7):298A, 1997. | | |
| | C25 | Klinman DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> 93(7):2879-83, 2 Apr 1996. | | |
| | C26 | Krajewski W et al., A monomeric derivative of the cellular transcription factor CREB functions as a constitutive activator. <i>Mol Cell Biol</i> 14(11):7204-10, Nov 1994. | | |
| | C27 | Krieg AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>J Lab Clin Med</i> 128(2):128-33, Aug 1996. | | |
| ✓ | C28 | Krieg AM et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. <i>J Immunol</i> 143(8):2448-51, 15 Oct 1989. | | |



| | | | |
|---|-----|---|------------|
| FORM PTO 08929 (Modified) | | ATTY. DOCKET NO. C1041/7005 | SERIAL NO. |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT | | APPLICANT: Lipford, et al. | |
| | | FILING DATE July 22, 1999 | GROUP |
| 93 | C29 | Krieg AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 6 Apr 1995. | |
| 93 | C30 | Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9, Summer 1996. | |
| | C31 | Krieg AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> 1(2):161-71, Summer 1991. | |
| | C32 | Kuramoto E et al., Oligonucleotide sequences required for natural killer cell activation. <i>Jpn J Cancer Res</i> 83(11):1128-31, Nov 1992. | |
| | C33 | Kwok RP et al., Nuclear protein CBP is a coactivator for the transcription factor CREB. <i>Nature</i> 370:223-6, 21 Jul 1994. | |
| | C34 | Lee KA and Masson N, Transcriptional regulation by CREB and its relatives. <i>Biochim Biophys Acta</i> 1174(3):221-33, 23 Sep 1993. | |
| | C35 | Leonard GA et al., Conformation of guanine-8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(08A)GCG). <i>Biochemistry</i> 31(36):8415-20, 15 Sep 1992. | |
| | C36 | Liu F and Green MR, Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains. <i>Nature</i> 368:520-5, 7 Apr 1994. | |
| | C37 | McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev</i> 3(4):309-22, Winter 1993. | |
| | C38 | Messina JP et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. <i>Cell Immunol</i> 147(1):148-57, Mar 1993. | |
| | C39 | Messina JP et al., Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. <i>J Immunol</i> 147(6):1759-64, 15 Sep 1991. | |
| | C40 | Mottram JC et al., A novel CDC2-related protein kinase from <i>Leishmania mexicana</i> , LmmCRK1, is post-translationally regulated during the life cycle. <i>J Biol Chem</i> 268(28):21044-52, 5 Oct 1993. | |
| | C41 | Nyce JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. <i>Nature</i> 385(6618):721-5, 20 Feb 1997. | |
| | C42 | Peterson, M., et al., Transcription Factors: A New Frontier in Pharmaceutical Development, <i>Bio Pharm</i> , 47:1:127-128 | |
| | C43 | Pisetsky DS and Reich CF, Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Sci</i> 54(2):101-7, 1994. | |
| | C44 | Rojanasakul Y, Antisense oligonucleotide therapeutics: drug delivery and targeting. <i>Adv Drug Delivery Rev</i> 18:115-131, 1996. | |
| | C45 | Roman M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med</i> 3(8):849-54, Aug 1997. | |
| | C46 | Sato Y et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. <i>Science</i> 273(5273):352-4, 19 Jul 1996. | |
| | C47 | Schnell N and Entian KD, Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators. <i>Eur J Biochem</i> 200(2):487-93, 1 Sep 1991. | |
| | C48 | Stein CA and Cohen JS, Oligodeoxynucleotides as inhibitors of gene expression: a review. <i>Cancer Res</i> 48(10):2659-68, 15 May 1988. | |
| | C49 | Stull RA and Szoka FC Jr, Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. <i>Pharm Res</i> 12(4):465-83, Apr 1995. | |
| ✓ | C50 | Tanaka T et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. <i>J Exp Med</i> 175(2):597-607, Feb 1992. | |



| | | | |
|---|-----|--|------------|
| FORM PTO-1449 (Modified) | | ATTY. DOCKET NO. C1041/7005 | SERIAL NO. |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT | | APPLICANT: Lipford, et al. | |
| | | FILING DATE July 22, 1999 | GROUP |
| <input checked="" type="checkbox"/> | C51 | Tokunaga T et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol</i> 36(1):55-66, 1992. | |
| <input checked="" type="checkbox"/> | C52 | Tokunaga T et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res</i> 79(6):682-6, Jun 1988. | |
| <input type="checkbox"/> | C53 | Uhlmann E and Peyman A, Antisense oligonucleotides: a new therapeutic principle. <i>Chem Rev</i> 90(4):543-84, Jun 1990. | |
| <input type="checkbox"/> | C54 | Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. <i>Nature</i> 372(6504):333-5, 24 Nov 1994. | |
| <input type="checkbox"/> | C55 | Wallace RB and Miyada CG, Oligonucleotide probes for the screening of recombinant DNA libraries. <i>Methods Enzymol</i> 152:432-442, 1987. | |
| <input type="checkbox"/> | C56 | Weiss R, Upping the antisense ante: scientists bet on profits from reverse genetics. <i>Science News</i> 139:108-109, 16 Feb 1991. | |
| <input type="checkbox"/> | C57 | Whalen RG, DNA vaccines for emerging infectious diseases: what if? <i>Emerg Infect Dis</i> 2(3):168-75, 1996. | |
| <input type="checkbox"/> | C58 | Wu-Pong S, Oligonucleotides: opportunities for drug therapy and research. <i>Pharm Technol</i> 18:102-114, Oct 1994. | |
| <input type="checkbox"/> | C59 | Xie H et al., Induction of CREB activity via the surface Ig receptor of B cells. <i>J Immunol</i> 151(2):880-9, 15 Jul 1993. | |
| <input type="checkbox"/> | C60 | Yamamoto S, Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG. <i>Kekkaku</i> 69(9):571-4, Sep 1994. | |
| <input type="checkbox"/> | C61 | Yamamoto S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol</i> 36(9):983-97, 1992. | |
| <input type="checkbox"/> | C62 | Yamamoto S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. <i>J Immunol</i> 148(12):4072-6, 1992. | |
| <input type="checkbox"/> | C63 | Yamamoto T et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev</i> 4(2):119-22, Summer 1994. | |
| <input type="checkbox"/> | C64 | Yamamoto T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol</i> 38(10):831-6, 1994. | |
| <input type="checkbox"/> | C65 | Yamamoto T et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <i>Jpn J Cancer Res</i> 85(8):775-9, Aug 1994. | |
| <input type="checkbox"/> | C66 | Yi AK et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. <i>J Immunol</i> 157(12):5394-402, 15 Dec 1996. | |
| <input type="checkbox"/> | C67 | Zhao Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> 3(1):53-66, Spring 1993. | |
| <input type="checkbox"/> | C68 | Zhao Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> 84(11):3660-6, 1 Dec 1994. | |
| <input checked="" type="checkbox"/> | C69 | New England Biolabs Catalog, 1988-1989, item #1230. | |
| Examiner | | Date Considered 3/29/04 | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/355,254

ATTY. DOCKET NO.: C1041.70005US00

FILING DATE: February 22, 2000

CONFIRMATION NO.: 6183

APPLICANT: Wagner et al.

GROUP ART UNIT: 1635

EXAMINER: Jane J. Zara

Sheet 1 of 1

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YYYY |
|------------------------|-------------|----------------------|--------------|--|--|
| | | Number | Kind Code | | |
| JZ | A37 | 2004/0009949 | A1 | Krieg | 01-15-2004 |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|------------------------|-------------|-------------------------|--------|--------------|---|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) | |
|------------------------|-------------|---|----------------------|--|
| | | | | |
| JZ | | | | |
| | | | | |
| | | | | |

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

| | | |
|---|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICATION NO.: 09/355,254 | ATTY. DOCKET NO.: C1041.70005US00 |
| | FILING DATE: February 22, 2000 | CONFIRMATION NO.: 6183 |
| | APPLICANT: Wagner et al. | |
| | GROUP ART UNIT: 1635 | EXAMINER: Jane J. Zara |

Sheet 1 of 1

CANCELLED
DEC 19 2003

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YY |
|------------------------|--------------|----------------------|-----------------|--|--|
| | | Number | Kind Code | | |
| J3 | A16 | 2003/0055014 | A1 | Bratzler | 03-20-2002 |
| | A17 | 2002/0064515 | A1 | Krieg et al. | 05-30-2002 |
| | A18 | 2002/0091097 | A1 | Bratzler et al. | 07-11-2002 |
| | A19 | 2002/0156033 | A1 | Bratzler et al. | 10-24-2002 |
| | A20 | 2002/0164341 | A1 | Davis et al. | 11-07-2002 |
| | A21 | 2002/0165178 | A1 | Schetter et al. | 11-07-2002 |
| | A22 | 2002/0198165 | A1 | Bratzler et al. | 12-26-2002 |
| | A23 | 2003/0026801 | A1 | Weiner et al. | 02-06-2003 |
| | A24 | 2003/0050261 | A1 | Krieg et al. | 03-13-2003 |
| | A25 | 2003/0050263 | A1 | Krieg et al. | 03-13-2003 |
| | A26 | 2003/0050268 | A1 | Krieg et al. | 03-13-2003 |
| | A27 | 2003/0087848 | A1 | Bratzler et al. | 05-08-2003 |
| | A28 | 2003/0091599 | A1 | Davis et al. | 05-15-2003 |
| | A29 | 2003/0100527 | A1 | Krieg et al. | 05-29-2003 |
| | A30 | 2003/0104523 | A1 | Lipford et al. | 06-05-2003 |
| | A31 | 2003/0139364 | A1 | Krieg et al. | 07-24-2003 |
| | A32 | 2003/0148976 | A1 | Krieg et al. | 08-07-2003 |
| | A33 | 2003/0148316 | A1 | Lipford et al. | 08-07-2003 |
| A34 | 2003/0166001 | A1 | Lipford | 09-04-2003 | |
| A35 | 2003/0181406 | A1 | Schetter et al. | 09-25-2003 | |
| A36 | 2003/0191079 | A1 | Krieg et al. | 10-09-2003 | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|------------------------|-------------|-------------------------|-----------|--------------|---|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| J3 | B32 | WO | 02/069369 | A2 | | 09-06-2002 | |

| | |
|--------------|--------------------------|
| EXAMINER: J3 | DATE CONSIDERED: 3/29/04 |
|--------------|--------------------------|

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]